Axel Grothey, MD
Identifying biomarkers for patients with colorectal cancer (CRC) continues to be a topic of discussion among researchers in the field, according to Axel Grothey, MD.
on GI Malignancies, Grothey, a medical oncologist at Mayo Clinic, discussed current first-line treatments for patients with CRC and highlighted the importance of developing biomarkers for this population.
OncLive: Please provide an overview of your presentation.
I talked about first-line treatment for colorectal cancer. First of all, there is an abundance of new and established drugs that are available right now. The key question that we have is, “Which patient should receive which treatment?” There are some theories, but we are more interested in looking at biomarker-driven decisions.
... to read the full story